A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Sponsor:

COG

Sponsor Study ID:

AALL1621

CTO #:

103488

NCT Number:

NCT02981628

Phase:

II

Protocol Type:

Treatment

Age Group:

Both

Disease Sites:

Lymphoid Leukemia

Study Objectives:

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)